Dr Reddys Laboratories addresses USFDA concern for three sites

Dr Reddys Laboratories announced that with regard to the receipt of Warning Letter from US FDA for three of its sites (API manufacturing facilities at Srikakulum, Andhra Pradesh and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh); the company has now been informed by US FDA that based on its evaluation, the company has addressed the violations and deviations contained in the said Warning Letter.

With this the said Warning Letter has been closed.

Powered by Capital Market - Live News